title: Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation.
abstract: The purpose of this study was to identify characteristics significant to survival and progression-free survival in patients with advanced ovarian cancer receiving high-dose chemotherapy. In all, 96 patients received autologous stem cell transplantation. Regimens included paclitaxel with carboplatin (PC), topotecan, melphalan, cyclophosphamide (TMC) and cyclophosphamide, BCNU, thiotepa (CBT). At the time of transplantation, 43% of patients were in clinical CR, 34% were in clinical PR, 18% had progressive disease and 5% had stable disease. There were no treatment-related deaths. The 6-year survival by Kaplan-Meier was 38%. For patients who received transplantation for remission consolidation, the 6-year survival was 53% with a PFS of 29%. On univariate analysis, the CBT regimen, clear cell histology and disease status other than CR prior to treatment were statistically significant adverse prognostic factors. This analysis has demonstrated that patients in clinical remission are most likely to benefit from autologous transplantation, with the exception of patients with clear cell histology. The TMC combination appeared to be superior to the PC and CBT combinations. Comparative studies of different consolidation approaches will be necessary to determine if autologous transplantation is the preferred treatment for this patient population.
authors.affiliation: Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. mdonato@mdanderson.org
authors.forename: M L
authors.initials: ML
authors.lastname: Donato
authors.forename: A
authors.initials: A
authors.lastname: Aleman
authors.forename: R E
authors.initials: RE
authors.lastname: Champlin
authors.forename: R M
authors.initials: RM
authors.lastname: Saliba
authors.forename: J T
authors.initials: JT
authors.lastname: Wharton
authors.forename: T W
authors.initials: TW
authors.lastname: Burke
authors.forename: D C
authors.initials: DC
authors.lastname: Bodurka
authors.forename: M W
authors.initials: MW
authors.lastname: Bevers
authors.forename: C F
authors.initials: CF
authors.lastname: Levenback
authors.forename: J K
authors.initials: JK
authors.lastname: Wolf
authors.forename: R C
authors.initials: RC
authors.lastname: Bast
authors.forename: R S
authors.initials: RS
authors.lastname: Freedman
authors.forename: C
authors.initials: C
authors.lastname: Ippoliti
authors.forename: M
authors.initials: M
authors.lastname: Brewer
authors.forename: J L
authors.initials: JL
authors.lastname: Gajewski
authors.forename: D M
authors.initials: DM
authors.lastname: Gershenson
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods*; D014182:Transplantation, Autologous; D016896:Treatment Outcome